TransMedics Group, Inc. (TMDX) SEC Filings & Earnings Calls

CFO transition risk is low given orderly succession and guidance reaffirmation.

“New CFO has extensive public-company finance leadership; outgoing CFO remains as advisor for LATAM expansion.”

Operating expenses increased significantly due to planned investments, pressuring near-term profitability.

“Operating expenses for the second quarter of 2026 were $89.5 million compared to $60.0 million in the second quarter of 2025.” · word for word

Net income declined 58% YoY despite revenue growth, due to investment spending.

“Net income of $14.7 million, or $0.41 per diluted share, compared to net income of $34.9 million, or $0.92 per diluted share.” · word for word

Dependence on NOP and OCS Liver growth

“Revenue growth is heavily concentrated in OCS Liver and NOP services; any disruption could materially impact results.”

Regulatory changes in OPTN

“The impact that HRSA’s initiatives and the U.S. Organ Procurement and Transplantation Network Act may have on our business, including on our NOP, is uncertain at this time.” · word for word

Tariff and trade policy risk

“Tariffs related to a small portion of components that we import moderately increased our cost of revenue in 2025.” · word for word

Gross margin pressure from product mix and freight costs

“Gross margin from net product revenue decreased from the three months ended March 31, 2025 to the three months ended March 31, 2026 primarily due to product mix and higher freight costs.” · word for word

Tariff exposure on imported components

“For example, tariffs related to a small portion of components that we import moderately increased our cost of revenue in 2025.” · word for word

OPTN restructuring uncertainty

“The impact that HRSA’s initiatives and the U.S. Organ Procurement and Transplantation Network Act may have on our business, including on our NOP, is uncertain at this time.” · word for word

Operating margin compression due to heavy investment spend may pressure near-term profitability.

“Operating margin declined from 19.1% to 7.6% YoY; adjusted operating margin from 20.7% to 10.4%”

Dependence on OCS program and NOP model for growth; any disruption could impact revenue.

“Revenue increase due primarily to OCS utilization in Liver and Heart through NOP”

Clinical Trial Delays

“The partial achievement of such goals was attributable to unusual and unexpected delays by FDA review of the pre-clinical testing, which delayed the approval of the IDE to initiate the clinical trials.” · word for word

Regulatory Approval Risk

“The partial achievement of such goals was attributable to unusual and unexpected delays by FDA review of the pre-clinical testing, which delayed the approval of the IDE to initiate the clinical trials.” · word for word

Key Personnel Dependence

“Dr. Hassanein is our founder, President and CEO, and his departure could impact the company.”

Net income inflated by one-time tax benefit of $103.3M from valuation allowance release.

“Net income includes a net income tax benefit of $83.8 million primarily due to the release of the valuation allowance related to deferred tax assets.”

Gross margin slightly declining due to higher clinical service expenses and freight costs.

“Gross margin 58% in Q4 2025 vs 59% prior year; change from prior year is a result of higher clinical service expenses in support of NOP expansion and higher freight cost.”

Dependence on single-source suppliers

“We rely on single-source suppliers and, in a few cases, sole-source suppliers for many of the components used in the OCS. For example, each of Fresenius Kabi Austria GmbH and Fresenius Kabi AB, which we refer to collectively as Fresenius, is our single-source supplier of OCS Solutions for the OCS Lung and the OCS Heart, respectively.” · word for word

NOP operational risk

“continued operations of our NOP depend on recruiting, training and retaining qualified surgeons, clinical specialists, pilots, and other personnel and establishing and maintaining effective coordination with transplant centers and regional Organ Procurement Organizations to locate donor organs and recipients.” · word for word

Short seller activist risk

“An activist short seller published a disparaging report about our business, which may impact our reputation in the market and deter surgeons and transplant centers from adopting the OCS or utilizing our NOP. In addition, this activist short seller has submitted a petition to the FDA, requesting that the FDA suspend the PMA approval for the OCS and take other” · word for word

Customer concentration risk

“We generate a significant amount of our revenue from a limited number of customers.” · word for word

Debt service risk

“Servicing our 1.50% convertible senior notes due 2028 requires a significant amount of cash, and we may not have sufficient cash flow to pay our debt.” · word for word

Key executive departures may cause temporary operational disruption.

“Transition of CCO and GC with non-executive roles and consulting periods.”

Significant lease obligation with 192-month term and 2% annual rent escalations; potential liquidity risk if revenue growth does not materialize.

“Lease will expire one hundred ninety-two (192) months from the Rent Commencement Date” · word for word

Material weakness in internal control over financial reporting

“that we have identified a material weakness in our internal control over financial reporting, and that” · word for word

Dependence on aviation fleet for NOP operations

“fueled by the continued expansion and utilization of our aviation fleet” · word for word

Short seller allegations and independent review costs

“Professional and consultant fees increased by $7.0 million due primarily to increased professional and legal fees related to an independent review of business practices following allegations raised in a short seller report released in January 2025.” · word for word

Tariff impact on cost of revenue

“We currently expect that tariffs related to a small portion of components that we import will moderately increase our cost of revenue in 2025.” · word for word

Dependence on OPTN regulatory changes

“The impact that HRSA's initiatives and the U.S. Organ Procurement and Transplantation Network Act may have on our business, including on our NOP, is uncertain at this time.” · word for word